ArticleNeuro-oncology advances
Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 47 citations in OpenAlex.
- Article
- Evolving landscape of glioblastoma research : A 75-year bibliometric study on survival, treatment and gender in authorship.Wiener klinische Wochenschrift · 2026Review
- Identification of new prognostic molecular markers in glioblastoma: a single-center retrospective study.The oncologist · 2026Article
- Overexpression of key complement regulators in glioblastoma.PloS one · 2026Article
- Clinical trial design for primary brain tumors: a problem-based framework for neuro-oncology practice.Frontiers in oncology · 2026Review
- Unveiling regional differences in glioblastoma patient survival with real-world data from the Norwegian brain tumor quality registry.Journal of neuro-oncology · 2025Article
- Factors associated with poor prognosis in elderly biopsy-only glioblastoma patients.Acta neurochirurgica · 2025Article
- Severe temozolomide-induced thrombocytopenia is linked to increased healthcare utilization in glioblastoma and disproportionally impacts female patients.Neuro-oncology practice · 2025Article
- Impact of alternating electric fields therapy for newly diagnosed WHO grade 4 astrocytoma on patient survival: a real-world propensity-score adjusted prospective multicenter study.Journal of neuro-oncology · 2025Article
- Cytoplasmic connexin43-microtubule interactions promote glioblastoma stem-like cell maintenance and tumorigenicity.Cell death & disease · 2025Article
- Article
- The Complexity of Malignant Glioma Treatment.Cancers · 2025Review
- The impact of cancer patient pathway on timing of radiotherapy and survival: a cohort study in glioblastoma patients.Journal of neuro-oncology · 2024Article
- Review
- Stable glioma incidence and increased patient survival over the past two decades in Norway: a nationwide registry-based cohort study.Acta oncologica (Stockholm, Sweden) · 2024Article
- Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024Review
- Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study.Neuro-oncology practice · 2024Article
- Functional and Molecular Heterogeneity in Glioma Stem Cells Derived from Multiregional Sampling.Cancers · 2023Article
- Segmentation of glioblastomas in early post-operative multi-modal MRI with deep neural networks.Scientific reports · 2023Article
- Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?Translational cancer research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe survival rates in population-based series of glioblastoma (GBM) differ substantially from those reported in clinical trials. This discrepancy may be attributed to that patients recruited to trials tend to be younger with better performance status. However, the proportion and characteristics of the patients in a population considered either eligible or ineligible for trials is unknown. The generalizability of trial results is therefore also uncertain.
methodsUsing the Cancer Registry of Norway and the Brain Tumor Database at Oslo University Hospital, we tracked all patients within a well-defined geographical area with newly diagnosed GBM during the years 2012-2017. Based on data from these registries and the medical records, the patients were evaluated for trial eligibility according to criteria employed in recent phase III trials for GBM.
resultsWe identified 512 patients. The median survival was 11.7 months. When we selected a potential trial population at the start of concurrent chemoradiotherapy (radiotherapy [RT]/ temozolomide [TMZ]) by the parameters age (18-70 y), passed surgery for a supratentorial GBM, Eastern Cooperative Oncology Group (ECOG) ≤2, normal hematologic, hepatic and renal function, and lack of severe comorbidity, 57% of the patients were excluded. Further filtering the patients who progressed during RT/TMZ and never completed RT/TMZ resulted in exclusion of 59% and 63% of the patients, respectively. The survival of patients potentially eligible for trials was significantly higher than of the patients not fulfilling trial eligibility criteria (
conclusionsPatients considered eligible for phase III clinical trials represent a highly selected minority of patients in a real-world GBM population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.